Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 21 January 2026, providing investors with the latest insights into its performance and prospects.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a modest daily price increase, the stock remains under pressure over longer time horizons, with technical parameters signalling a transition from bearish to mildly bearish trends.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 30 December 2025, providing investors with an up-to-date analysis of the company’s position.

Sun Pharma Advanced Research Company (SPARC) has experienced a notable shift in its technical momentum, reflecting evolving market dynamics and investor sentiment within the Pharmaceuticals & Biotechnology sector. Recent assessment changes highlight a transition in key technical indicators, signalling a more cautious outlook as the stock navigates a challenging environment.

Sun Pharma Advanced Research Company demonstrated robust intraday performance on 19 Dec 2025, reaching a day’s high of Rs 141.95, reflecting a 7.78% rise during the trading session. The stock outpaced its sector and broader market indices, supported by sustained buying interest and favourable technical positioning.

SPARC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its evaluation metrics reflecting ongoing financial and operational challenges. This shift highlights the company’s current standing amid a difficult market environment and evolving sector dynamics.

Sun Pharma Advanced Research Company (SPARC) has exhibited a nuanced shift in its technical landscape, reflecting a complex interplay of momentum indicators and moving averages. Recent market data reveals a transition in price momentum, with technical parameters signalling a blend of cautious optimism and persistent challenges within the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company (SPARC) is exhibiting a notable shift in price momentum as recent technical indicators reveal a predominantly bearish outlook. The stock’s performance contrasts sharply with broader market trends, underscoring challenges within the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company experienced a notable decline today, touching an intraday low of Rs 140.4, reflecting a price pressure of 8.15% during the session. This underperformance contrasted with broader market movements and sector trends, signalling immediate pressures on the stock.

Sun Pharma Advanced Research Company recorded a robust intraday performance today, reaching a high of Rs 174.25, reflecting an 8.16% rise during the trading session. The stock outpaced its sector and broader market indices, demonstrating notable volatility and sustained upward momentum.

Sun Pharma Advanced Research Company Ltd has witnessed extraordinary buying momentum, with the stock hitting an upper circuit and only buy orders in the queue, signalling a potential multi-day rally amid strong investor enthusiasm.

Sun Pharma Advanced Research Company recorded a robust intraday performance today, reaching a high of Rs 145.95, reflecting an 8.72% rise amid heightened volatility and notable trading activity.

SPARC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing financial and operational challenges. This shift highlights the company’s current standing amid a difficult market environment and persistent underperformance relative to its peers and benchmarks.

Sun Pharma Advanced Research Company (SPARC) has experienced a notable shift in its technical parameters, reflecting a nuanced change in price momentum. Recent data reveals a transition from a predominantly bearish stance to a mildly bearish outlook, with key technical indicators such as MACD, RSI, and moving averages presenting a complex picture for investors analysing the pharmaceutical and biotechnology sector.

Sun Pharma Advanced Research Company (SPARC) is currently exhibiting a notable shift in its technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent evaluation adjustments highlight a transition in key technical indicators, signalling a more cautious outlook for investors amid broader market pressures.

Sun Pharma Advanced Research Company (SPARC) has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and investor sentiment within the Pharmaceuticals & Biotechnology sector. Recent price movements and technical indicators suggest a nuanced transition in the stock’s trend, warranting close attention from market participants.